Bruce Belanger

2.4k total citations
59 papers, 865 citations indexed

About

Bruce Belanger is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Bruce Belanger has authored 59 papers receiving a total of 865 indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 14 papers in Molecular Biology and 14 papers in Epidemiology. Recurrent topics in Bruce Belanger's work include Pancreatic and Hepatic Oncology Research (34 papers), Lung Cancer Research Studies (12 papers) and Cancer therapeutics and mechanisms (12 papers). Bruce Belanger is often cited by papers focused on Pancreatic and Hepatic Oncology Research (34 papers), Lung Cancer Research Studies (12 papers) and Cancer therapeutics and mechanisms (12 papers). Bruce Belanger collaborates with scholars based in United States, Taiwan and Spain. Bruce Belanger's co-authors include Li‐Tzong Chen, Jens T. Siveke, Andrea Wang‐Gillam, Floris A. de Jong, Richard Hubner, Daniel D. Von Hoff, Beloo Mirakhur, Teresa Macarulla, Jean‐Frédéric Blanc and Yun‐Fan Liaw and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Bruce Belanger

52 papers receiving 851 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruce Belanger United States 15 467 377 242 160 138 59 865
Yuebo Yang China 16 215 0.5× 290 0.8× 218 0.9× 312 1.9× 37 0.3× 43 944
Hyun Young Woo South Korea 22 329 0.7× 515 1.4× 757 3.1× 179 1.1× 246 1.8× 71 1.3k
Eléonora De Martin France 14 605 1.3× 278 0.7× 400 1.7× 126 0.8× 243 1.8× 47 1.1k
Caecilia Sukowati Italy 16 227 0.5× 197 0.5× 222 0.9× 429 2.7× 50 0.4× 47 848
Leonardo Gomes da Fonseca Brazil 15 318 0.7× 172 0.5× 350 1.4× 161 1.0× 132 1.0× 68 804
Chen Zhou China 14 118 0.3× 224 0.6× 348 1.4× 150 0.9× 186 1.3× 60 713
Chiara Caparello Italy 15 569 1.2× 121 0.3× 291 1.2× 325 2.0× 244 1.8× 45 1.2k
Ioannis Varthalitis Greece 19 581 1.2× 173 0.5× 70 0.3× 186 1.2× 58 0.4× 47 836
Akhil Chopra Singapore 14 350 0.7× 139 0.4× 343 1.4× 101 0.6× 82 0.6× 27 750
Jun Lei China 20 240 0.5× 172 0.5× 168 0.7× 472 3.0× 200 1.4× 51 991

Countries citing papers authored by Bruce Belanger

Since Specialization
Citations

This map shows the geographic impact of Bruce Belanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Belanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Belanger more than expected).

Fields of papers citing papers by Bruce Belanger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce Belanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Belanger. The network helps show where Bruce Belanger may publish in the future.

Co-authorship network of co-authors of Bruce Belanger

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce Belanger. A scholar is included among the top collaborators of Bruce Belanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce Belanger. Bruce Belanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
McKenzie, Katherine, et al.. (2025). Late Mortality Among Survivors of Childhood Cancer in Canada: A Retrospective Cohort Study. Pediatric Blood & Cancer. 72(7). e31700–e31700. 1 indexed citations
2.
Winchester, Lee C., et al.. (2024). Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19. Journal of Antimicrobial Chemotherapy. 79(6). 1423–1431. 1 indexed citations
3.
Lickliter, Jason D., et al.. (2024). First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus. Antimicrobial Agents and Chemotherapy. 68(5). e0161523–e0161523. 6 indexed citations
4.
Horga, Alejandro, Giorgio Morelli, Keith Pietropaolo, et al.. (2021). High lung levels of active triphosphate predicted with oral at-527 in COVID patients. 29(1). 127–127. 1 indexed citations
5.
Chen, Li‐Tzong, Teresa Macarulla, Jean-Frédéric Blanc, et al.. (2020). Early dose reduction/delay and the efficacy of liposomal irinotecan with fluorouracil and leucovorin in metastatic pancreatic ductal adenocarcinoma (mPDAC): A post hoc analysis of NAPOLI-1. Pancreatology. 21(1). 192–199. 8 indexed citations
6.
Sachdev, Jasgit C., Pamela N. Münster, Donald W. Northfelt, et al.. (2020). Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Research and Treatment. 185(3). 759–771. 33 indexed citations
7.
8.
Wang‐Gillam, Andrea, Richard Hubner, Jens T. Siveke, et al.. (2019). NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. European Journal of Cancer. 108. 78–87. 199 indexed citations
9.
10.
Hubner, Richard, Antonio Cubillo, Jean‐Frédéric Blanc, et al.. (2018). Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorin. European Journal of Cancer. 106. 24–33. 36 indexed citations
11.
Macarulla, Teresa, Jean‐Frédéric Blanc, Beloo Mirakhur, et al.. (2018). Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1. Annals of Oncology. 29. viii250–viii251. 4 indexed citations
12.
13.
14.
15.
16.
17.
18.
19.
Arico-Muendel, Christopher C., Bruce Belanger, Dennis R. Benjamin, et al.. (2013). Metabolites of PPI-2458, a Selective, Irreversible Inhibitor of Methionine Aminopeptidase-2: Structure Determination and In Vivo Activity. Drug Metabolism and Disposition. 41(4). 814–826. 9 indexed citations
20.
Zeuzem, Stefan, Edward Gane, Yun‐Fan Liaw, et al.. (2009). Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B. Journal of Hepatology. 51(1). 11–20. 156 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuebo Yang Breakdown of academic impact, for papers by Hyun Young Woo Breakdown of academic impact, for papers by Eléonora De Martin Breakdown of academic impact, for papers by Caecilia Sukowati Breakdown of academic impact, for papers by Leonardo Gomes da Fonseca Breakdown of academic impact, for papers by Chen Zhou Breakdown of academic impact, for papers by Chiara Caparello Breakdown of academic impact, for papers by Ioannis Varthalitis Breakdown of academic impact, for papers by Akhil Chopra Breakdown of academic impact, for papers by Jun Lei
Rankless by CCL
2026